Floatz logo

ly3556050

Osteoarthritis, Knee

Eli Lilly and CompanyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

30 Active assets in the Osteoarthritis, Knee cohort.

Asset / SponsorPhaseRating
Duloxetine
Orthopaedic Arthroscopy Knee and Shoulder Clinic
Phase 4BBB
Naproxen
Pfizer
Phase 3BB
Triamcinalone
Mayo Clinic
Phase 4BB
DEXTROSE SOLUTION
Kastamonu University
Phase 4BB
Remimazolam
Seoul National University Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

ly3556050 is also rated in:

diabetic neuropathyDormant
B
Indicative ·
57 / 100
View asset →
diabetic neuropathyDormant
B
Indicative ·
57 / 100
View asset →
osteoarthritisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →